THREE INTERNATIONAL TOWERS LEVEL 24,, SYDNEY NSW, C3
Appoints James Levine as Chief Financial Officer
Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Financial Insights Cash & Cash Equivalents: ~ US$46 million (Runway expected to fund planned operations into 2029, excluding additional or expanded trials)
Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Enters Into License and Commercialisation Agreement
Strategic Advancements in Oncology Pipeline
Enters Into Sales Agreement with Leerink Partners LLC
Half-Year Report for the Six Months Ended December 31, 2025
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(3)
No filings found
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
NT 20-F